Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Koroki K, et al. Among authors: kiyono s. Liver Cancer. 2021 Apr 20;10(5):473-484. doi: 10.1159/000515552. eCollection 2021 Sep. Liver Cancer. 2021. PMID: 34721509 Free PMC article.
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, Kiyono S, Nakamura M, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N. Ogasawara S, et al. Among authors: kiyono s. Invest New Drugs. 2018 Apr;36(2):332-339. doi: 10.1007/s10637-017-0507-3. Epub 2017 Sep 11. Invest New Drugs. 2018. PMID: 28891038
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Ogasawara S, et al. Among authors: kiyono s. Invest New Drugs. 2020 Feb;38(1):172-180. doi: 10.1007/s10637-019-00801-8. Epub 2019 Jun 6. Invest New Drugs. 2020. PMID: 31172442
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.
Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Maruta S, et al. Among authors: kiyono s. Liver Cancer. 2020 Aug;9(4):382-396. doi: 10.1159/000507022. Epub 2020 May 5. Liver Cancer. 2020. PMID: 32999866 Free PMC article.
Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.
Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Koroki K, et al. Among authors: kiyono s. Liver Cancer. 2020 Sep;9(5):596-612. doi: 10.1159/000508809. Epub 2020 Jul 22. Liver Cancer. 2020. PMID: 33083283 Free PMC article.
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma.
Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, Ma Y, Kojima R, Kusakabe Y, Nakamura M, Kobayashi K, Kiyono S, Kanogawa N, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Kato J, Kanda T, Maruyama H, Kato N. Ao J, et al. Among authors: kiyono s. J Cancer. 2021 Mar 5;12(9):2694-2701. doi: 10.7150/jca.56436. eCollection 2021. J Cancer. 2021. PMID: 33854629 Free PMC article.
Changes in therapeutic options for hepatocellular carcinoma in Asia.
Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Ogasawara S, et al. Among authors: kiyono s. Liver Int. 2022 Aug;42(9):2055-2066. doi: 10.1111/liv.15101. Epub 2021 Nov 29. Liver Int. 2022. PMID: 34780081 Review.
Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma.
Kondo T, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Ogasawara S, Ooka Y, Nakamoto S, Chiba T, Arai M, Kato J, Kuboki S, Ohtsuka M, Kato N. Kondo T, et al. Among authors: kiyono s. PLoS One. 2022 Jan 27;17(1):e0261619. doi: 10.1371/journal.pone.0261619. eCollection 2022. PLoS One. 2022. PMID: 35085277 Free PMC article.
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Kobayashi K, et al. Among authors: kiyono s. Liver Cancer. 2021 Dec 6;11(1):48-60. doi: 10.1159/000519868. eCollection 2022 Jan. Liver Cancer. 2021. PMID: 35222507 Free PMC article.
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience.
Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, Zhang J, Yumita S, Ishino T, Unozawa H, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Kanda T, Maruyama H, Mimura N, Kato J, Motohashi S, Kato N. Ogawa K, et al. Among authors: kiyono s. J Cancer. 2022 May 16;13(8):2656-2661. doi: 10.7150/jca.71494. eCollection 2022. J Cancer. 2022. PMID: 35711837 Free PMC article.
139 results